Latest Conference Articles

Steve Deitelzweig, MD, discussed the real-world usage of direct-acting anticoagulants in comparison with the conventional warfarin, as well as the benefits they have shown based on a large data analysis.

Hadley Wilson, MD, spoke about the new heart failure guidelines and how the ACC is attempting to make them more technologically available, as well as the ACC's efforts to connect with cardiologists on a more worldwide scale to help improve cardiac outcomes globally.

A novel subretinal implantation of a stem cell-based bioengineered patch may restore vision or prevent further vision loss.

Justin Davies, MBBS, MRCP, PhD, discussed the cost-effectiveness analysis of the DEFINE-FLAIR trial comparing iFR and FFR for patients requiring PCI.

Incorporating underused, but available, imaging technologies like PET/CT to test for calcium in coronary arteries more precisely predicts those at risk for MI and similar threats.

While copayment reduction significantly affected clinician’s choice of medication and improved patient persistence with treatment, it did not impact clinical outcomes at 1 year.

Larry Allen, MD, was part of a deeper look into the hospital readmissions reduction program (HRRP), and what the data that have been presented about it actually mean.

For patients with heart failure, the influenza vaccine can result in a mortality reduction up to 50% in season and 20% out of season.

Listening to music may help prolong exercise and participation, and may possibly have broader implications for exercise.

Findings suggest climate change may increase MI risk.

The risk of myocardial infarction was 2.4-fold higher in patients on short-term P2Y12 inhibitors after 18 months and 5.1-fold higher from month 6 to month 18.

Andexanet was shown to reduce FXa inhibition activity by 91% for patients on apixaban, 88% for patients on rivaroxaban, and 75% for patients on enoxaparin.

No events of primary endpoint occurred in PFO closure arm, whereas it developed in 6 of 60 patients receiving medication therapy alone.

Aggressive supplementation with vitamin D3 just before and after surgery can completely eliminate the observed drop.

As canakinumab lowers hsCRP, as well as interleukin-6, without a negative effect on lipid levels, it characterizes a new class of atherosclerosis medications.

The combined efforts of coaxing from barbers and monthly in-shop care from pharmacists resulted in 63.6% of the cohort achieving target BP levels.

At 6 weeks 68% of those receiving the Triple Pill achieved a blood pressure within their target range, versus 44% of those receiving usual care.

The CVD-REAL 2 study found that compared with other glucose-lowering drugs, SGLT-2 inhibitors reduce all-cause death, hospitalization for heart failure, myocardial infarction, and stroke.

While receiving a large dose of statin therapy did not have an impact on major adverse cardiac events among a broad population of patients, those that underwent percutaneous coronary intervention saw reductions.

Patients that were more optimistic had fewer heart-related hospital visits.

The mSToPS trial revealed a wearable ECG patch can markedly increase the AFib diagnosis rate relative to routine care—as much as 9-fold in the short-term and 3-fold in the long-term.

MOMENTUM 3 found that advanced heart-failure patients with an implanted centrifugal-flow circulatory pump had lower rates of pump-related blood clots and stroke.

Studies reveal short- and long-term effects of heart changes in college and professional football players.

The use of instantaneous wave-free ratio can reportedly save each patient at least $800 in comparison with fractional flow reserve.

While full parity may be impossible, a 4-step protocol did decrease discrepancies in clinical outcomes and mortality between men and women.

Clinicians have been shown to be influenced by their patients’ genetic makeup when prescribing antiplatelet therapies.

All-cause mortality and death due to stroke, however, were 1.8% and 0.5% lower, respectively, in the group utilizing WCD.

Study sheds new light on potential risks and benefits of aspirin for people with both conditions.

The trial showed alirocumab reduced MACE by 24% with an ARR of 3.4% and all-cause death by 29% with an ARR of 1.7% in patients with ACS and baseline LDL-C ≥100 mg/dL.

The Vancouver, BC, retrospective cohort study found the HIV-schizophrenia population was mostly white, and mostly males.